Related Experiment Videos
[Efficacy of intravenous ceftazidime in childhood infections]
1Hacettepe Universitesi, Pediatri Anabilim Dali.
Insights
Ceftazidime effectively treated serious infections in 33 pediatric patients, including those with critical conditions and neutropenia. This beta-lactamase resistant cephalosporin demonstrated an 88% clinical response rate with no major adverse effects.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Context:
- Serious infections in pediatric patients often present complex challenges.
- High prevalence of underlying conditions (90%) and malignancy (72%) in the study cohort.
- Neutropenia (20 patients) is a significant risk factor for severe infections.
Purpose:
- To evaluate the efficacy and safety of intravenous ceftazidime in pediatric patients with serious infections.
- To assess clinical and microbiological outcomes in a diverse pediatric patient population.
- To determine the tolerability of ceftazidime in critically ill children.
Summary:
- Intravenous ceftazidime was administered to 33 pediatric patients (3 days–15 years) with serious infections.
- The patient group had a high burden of comorbidities, including critical illness (51.5%) and neutropenia.
- An overall clinical response rate of 88% was observed, with no major adverse events reported.
Impact:
- Ceftazidime offers an effective and safe therapeutic option for severe pediatric infections.
- Demonstrates utility in managing infections in immunocompromised and critically ill pediatric populations.
- Supports the use of ceftazidime as a reliable treatment for challenging pediatric infections.
Abstract:
Ceftazidime, a beta-lactamase resistant cephalosporin, was administered intravenously to 33 patients with various infections. The age range was between 3 days and 15 years and substantial underlying disease was present in 90% of the patients and 72% had malignancy. Seventeen (51.5%) were in critical condition and twenty had granulocytopenia. Clinical and microbiological results were evaluated and overall clinical response was 88%. No major adverse effects were encountered. Ceftazidime was an effective and safe therapy for serious infections and neutropenic patients.